The expression and clinical significance of serum ENAH in patients with HBV related hepatocellular carcinoma
Objective To investigate the clinical significance of serum actin modulators(enabled homolog,ENAH)in hepatitis B vi-rus related hepatocellular carcinoma(HBV-HCC).Methods The serum levels of ENAH were measured by ELISA in 67 patients with HBV-HCC,20 patients with nonHBV-HCC,60 patients with chronic hepatitis B(CHB)and 20 healthy controls(HC).Spearman's correlation analysis was used to examine the correlation between serum ENAH and tumor characteristics and laboratory indicators.Re-ceiver operator curves(ROCs)of ENAH,alpha fetoprotein(AFP)and their combination(Logistic regression model)in diagnosis of HBV-HCC were plotted.Results The expression levels of serum ENAH in the patients with HBV-HCC,nonHBV-HCC,CHB and HC were 8.5(7.0,8.9)ng/mL,5.5(4.0,6.0)ng/mL,7.3(5.0,7.9)ng/mL and 2.9(1.8,4.9)ng/mL,respectively.The differences among the groups were statistically significant(χ2=71.36,P＜0.001).The serum ENAH was positively correlated with BCLC(Barcelo-na Clinic Liver Cancer)and maximum tumor diameter(r=0.261 and 0.322,P=0.035 and 0.008);The area under ROC(AUCROC)of ENAH,AFP and their combination in diagnosis of HBV-HCC were 0.808(95%CI:0.735-0.868),0.782(95%CI:0.707-0.846)and 0.838(95%CI:0.768-0.894),respectively.The sensitivity and specificity of ENAH in diagnosing HBV-HCC were 62.69%(95%CI:50.0%-74.2%)and 90.0%(95%CI:81.2%-95.6%),respectively.Conclusion Serum ENAH is a potential serological marker for di-agnosis and evaluation of HBV-HCC.
enable homologhepatocellular carcinomahepatitis B virus
NETL
NSTL
万方数据
维普
